Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome

Diabetes Care

Volumn 29, Issue 12, 2006, Pages 2592-2597

  Bakris, George ^a,f   Molitch, Mark ^b   Hewkin, A ^c   Kipnes, Mark ^d   Sarafidis, Pantelis ^a   Fakouhi, Kaffa ^c   Bacher, Peter ^c   Sowers, James ^e  

^a RUSH UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

^d Endocrinology Practice   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INSULIN; LIPID; TRANDOLAPRIL PLUS VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DISEASE MARKER; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIMB PAIN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; ORAL GLUCOSE TOLERANCE TEST; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY SIZE; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INDOLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATIENT SELECTION; VERAPAMIL;

EID: 33845497759     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1373     Document Type: Article

References (18)

1. Sarafidis P, Bakris GL: Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care 29:1167-1169, 2006
2. Cooper-DeHoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ, the INVEST Investigators: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 98:890-894, 2006
3. Mancia G, Grassi G, Zanchetti A: Newonset diabetes and antihypertensive drugs. J Hypertens 24:3-10, 2006
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
5. Brady LM, Gower BA, Lovegrove SS, Williams CM, Lovegrove JA: Revised QUICKI provides a strong surrogate estimate of insulin sensitivity when compared with the minimal model. Int J Obes Relat Metab Disord 28:222-227, 2004
6. Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ: QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 284:E804-E812, 2004
7. Andersson OK, Gudbrandsson T, Jamerson K: Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med Suppl 735:89-96, 1991
8. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB: Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 19 (Suppl. 2):II26-II29, 1992
9. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL: Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48:219-224, 2006
10. ALLHAT Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
11. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989
12. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, Macdonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimsky J, Zanchetti A: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24:1405-1412, 2006
13. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S: Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 5:17-22, 2005
14. Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM, Elliot HL: Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 85:1882-1889, 2000
15. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT: Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metab Res 31:418-423, 1999
16. American Diabetes Association: Summary of revisions for the 2006 clinical practice recommendations. Diabetes Care 29 (Suppl. 1):S3, 2006
17. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963-969, 2004
18. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR: Longterm effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29-35, 2005